{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:19:43Z","timestamp":1761513583332},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,2,4]],"date-time":"2015-02-04T00:00:00Z","timestamp":1423008000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s12020-014-0506-5","type":"journal-article","created":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T03:49:50Z","timestamp":1422935390000},"page":"620-627","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros"],"prefix":"10.1007","volume":"49","author":[{"given":"Maurizio","family":"Rossini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Orsolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ombretta","family":"Viapiana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvano","family":"Adami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,4]]},"reference":[{"key":"506_CR1","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","volume":"18","author":"E Canalis","year":"2007","unstructured":"E. Canalis, G. Mazziotti, A. Giustina, J.P. Bilezikian, Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos. Int. 18, 1319\u20131328 (2007)","journal-title":"Osteoporos. Int."},{"key":"506_CR2","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1210\/me.2009-0069","volume":"23","author":"LC Hofbauer","year":"2009","unstructured":"L.C. Hofbauer, M. Rauner, Minireview: live and let die: molecular effects of glucocorticoids on bone cells. Mol. Endocrinol. 23, 1525\u20131531 (2009)","journal-title":"Mol. Endocrinol."},{"key":"506_CR3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1172\/JCI2799","volume":"102","author":"RS Weinstein","year":"1998","unstructured":"R.S. Weinstein, R.L. Jilka, A.M. Parfitt, S.C. Manolagas, Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 102, 274\u2013282 (1998)","journal-title":"J. Clin. Invest."},{"key":"506_CR4","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s00223-009-9303-1","volume":"85","author":"W Mak","year":"2009","unstructured":"W. Mak, X. Shao, C.R. Dunstan, M.J. Seibel, H. Zhou, Biphasic glucocorticoid-dependent regulation of Wnt expression and its inhibitors in mature osteoblastic cells. Calcif. Tissue Int. 85, 538\u2013545 (2009)","journal-title":"Calcif. Tissue Int."},{"key":"506_CR5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bbrc.2004.04.025","volume":"21","author":"K Ohnaka","year":"2004","unstructured":"K. Ohnaka, H. Taniguchi, H. Kawate, H. Nawata, R. Takayanagi, Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun. 21, 259\u2013264 (2004)","journal-title":"Biochem Biophys Res Commun."},{"key":"506_CR6","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1210\/en.2007-0910","volume":"149","author":"FS Wang","year":"2008","unstructured":"F.S. Wang, J.Y. Ko, D.W. Yeh, H.C. Ke, H.L. Wu, Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology 149, 1793\u20131801 (2008)","journal-title":"Endocrinology"},{"key":"506_CR7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00223-013-9749-z","volume":"93","author":"M Rossini","year":"2013","unstructured":"M. Rossini, D. Gatti, S. Adami, Involvement of WNT\/\u03b2-catenin signaling in the treatment of osteoporosis. Calcif. Tissue Int. 93, 121\u2013132 (2013)","journal-title":"Calcif. Tissue Int."},{"key":"506_CR8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/BF02405356","volume":"36","author":"V Lo Cascio","year":"1984","unstructured":"V. Lo Cascio, E. Bonucci, B. Imbimbo, P. Ballanti, D. Tartarotti, G. Galvanini, L. Fuccella, S. Adami, Bone loss after glucocorticoid therapy. Calcif. Tissue Int. 36, 435\u2013438 (1984)","journal-title":"Calcif. Tissue Int."},{"key":"506_CR9","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.tem.2006.03.009","volume":"17","author":"G Mazziotti","year":"2006","unstructured":"G. Mazziotti, A. Angeli, J.P. Bilezikian, E. Canalis, A. Giustina, Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol. Metab. 17, 144\u2013149 (2006)","journal-title":"Trends Endocrinol. Metab."},{"key":"506_CR10","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/rheumatology\/kem030","volume":"46","author":"G Saviola","year":"2007","unstructured":"G. Saviola, L. Abdi Ali, S. Shams Eddin, A. Coppini, F. Cavalieri, L. Campostrini, S. Sacco, M. Bucci, G. Cirino, Rossini M Compared clinical efficacy and bone metabolic effects of low-dose deflazacort and methyl prednisolone in male inflammatory arthropathies: a 12-month open randomized pilot study. Rheumatology 46, 994\u2013998 (2007)","journal-title":"Rheumatology"},{"key":"506_CR11","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1172\/JCI28084","volume":"116","author":"HJ Kim","year":"2006","unstructured":"H.J. Kim, H. Zhao, H. Kitaura, S. Bhattacharyya, J.A. Brewer, L.J. Muglia, F.P. Ross, S.L. Teitelbaum, Glucocorticoids suppress bone formation via the osteoclast. J. Clin. Invest. 116, 2152\u20132160 (2006)","journal-title":"J. Clin. Invest."},{"key":"506_CR12","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1210\/en.2006-0459","volume":"147","author":"D Jia","year":"2006","unstructured":"D. Jia, C.A. O\u2019Brien, S.A. Stewart, S.C. Manolagas, R.S. Weinstein, Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 147, 5592\u20135599 (2006)","journal-title":"Endocrinology"},{"key":"506_CR13","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1210\/endo.139.3.5778","volume":"139","author":"J Rubin","year":"1998","unstructured":"J. Rubin, D.M. Biskobing, L. Jadhav, D. Fan, M.S. Nanes, S. Perkins, X. Fan, Dexamethasone promotes expression of membrane-bound macrophage colony-stimulating factor in murine osteoblast-like cells. Endocrinology 139, 1006\u20131012 (1998)","journal-title":"Endocrinology"},{"key":"506_CR14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00198-013-2588-y","volume":"25","author":"A Scillitani","year":"2014","unstructured":"A. Scillitani, G. Mazziotti, C. Di Somma, S. Moretti, A. Stigliano, R. Pivonello, A. Giustina, A. Colao, Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how? Osteoporos. Int. 25, 441\u2013446 (2014)","journal-title":"Osteoporos. Int."},{"key":"506_CR15","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1359\/jbmr.080617","volume":"23","author":"LI Plotkin","year":"2008","unstructured":"L.I. Plotkin, V. Lezcano, J. Thostenson, R.S. Weinstein, S.C. Manolagas, T. Bellido, Connexin 43 is required for the antiapoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J. Bone Miner. Res. 23, 1712\u20131721 (2008)","journal-title":"J. Bone Miner. Res."},{"key":"506_CR16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00223-012-9630-5","volume":"91","author":"R Rizzoli","year":"2012","unstructured":"R. Rizzoli, J.D. Adachi, C. Cooper, W. Dere, J.P. Devogelaer, A. Diez-Perez, J.A. Kanis, A. Laslop, B. Mitlak, S. Papapoulos, S. Ralston, S. Reiter, G. Werhya, J.Y. Reginster, Management of glucocorticoid-induced osteoporosis. Calcif. Tissue Int. 91, 225\u2013243 (2012)","journal-title":"Calcif. Tissue Int."},{"key":"506_CR17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1056\/NEJM199708073370603","volume":"337","author":"JD Adachi","year":"1997","unstructured":"J.D. Adachi, W.G. Bensen, J. Brown, D. Hanley, A. Hodsman, R. Josse, D.L. Kendler, B. Lentle, W. Olszynski, L.G. Ste-Marie, A. Tenenhouse, Chines AA Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N. Engl. J. Med. 337, 382\u2013387 (1997)","journal-title":"N. Engl. J. Med."},{"key":"506_CR18","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1210\/jcem.83.4.4742","volume":"83","author":"C Roux","year":"1998","unstructured":"C. Roux, P. Oriente, R. Laan, R.A. Hughes, J. Ittner, S. Goemaere, O. Di Munno, J.M. Pouilles, S. Horlait, B. Cortet, Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group. J. Clin. Endocrinol. Metab. 83, 1128\u20131133 (1998)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"506_CR19","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/03009749950154211","volume":"28","author":"EA Jenkins","year":"1999","unstructured":"E.A. Jenkins, K.E. Walker-Bone, A. Wood, F.C. McCrae, C. Cooper, Cawley MI The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate. Scand. J. Rheumatol. 28, 152\u2013156 (1999)","journal-title":"Scand. J. Rheumatol."},{"key":"506_CR20","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1136\/ard.57.12.724","volume":"57","author":"P Geusens","year":"1998","unstructured":"P. Geusens, J. Dequeker, J. Vanhoof, R. Stalmans, S. Boonen, J. Joly, J. Nijs, J. Raus, Cyclical etidronate increases bone densityinthespine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. Ann. Rheum. Dis. 57, 724\u2013727 (1998)","journal-title":"Ann. Rheum. Dis."},{"key":"506_CR21","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/thx.53.5.351","volume":"53","author":"P Pitt","year":"1998","unstructured":"P. Pitt, F. Li, P. Todd, D. Webber, S. Pack, Moniz C A double blindplacebo controlled study todetermine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment. Thorax 53, 351\u2013356 (1998)","journal-title":"Thorax"},{"key":"506_CR22","first-page":"142","volume":"35","author":"S Sato","year":"2008","unstructured":"S. Sato, T. Takada, Y. Katsuki, N. Kimura, Y. Kaneko, A. Suwa, M. Hirakata, M. Kuwana, J Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup. Rheumatol. 35, 142\u2013146 (2008)","journal-title":"Rheumatol."},{"key":"506_CR23","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","volume":"339","author":"KG Saag","year":"1998","unstructured":"K.G. Saag, R. Emkey, T.J. Schnitzer, J.P. Brown, F. Hawkins, S. Goemaere, G. Thamsborg, U.A. Liberman, P.D. Delmas, M.P. Malice, M. Czachur, A.G. Daifotis, Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N. Engl. J. Med. 339, 292\u2013299 (1998)","journal-title":"N. Engl. J. Med."},{"key":"506_CR24","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","volume":"44","author":"JD Adachi","year":"2001","unstructured":"J.D. Adachi, K.G. Saag, P.D. Delmas, U.A. Liberman, R.D. Emkey, E. Seeman, N.E. Lane, J.M. Kaufman, P.E. Poubelle, F. Hawkins, R. Correa-Rotter, C.J. Menkes, J.A. Rodriguez-Portales, T.J. Schnitzer, J.A. Block, J. Wing, H.H. McIlwain, R. Westhovens, J. Brown, J.A. Melo-Gomes, B.L. Gruber, M.J. Yanover, M.O. Leite, K.G. Siminoski, M.C. Nevitt, J.T. Sharp, M.P. Malice, T. Dumortier, M. Czachur, W. Carofano, Daifotis A Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebocontrolled extension trial. Arthr. Rheum. 44, 202\u2013211 (2001)","journal-title":"Arthr. Rheum."},{"key":"506_CR25","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1359\/jbmr.2003.18.5.919","volume":"18","author":"PN Sambrook","year":"2003","unstructured":"P.N. Sambrook, M. Kotowicz, P. Nash, C.B. Styles, V. Naganathan, K.N. Henderson-Briffa, J.A. Eisman, Nicholson GC Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J. Bone Miner. Res. 18, 919\u2013924 (2003)","journal-title":"J. Bone Miner. Res."},{"key":"506_CR26","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJMoa035617","volume":"350","author":"E Shane","year":"2004","unstructured":"E. Shane, V. Addesso, P.B. Namerow, D.J. McMahon, S.H. Lo, R.B. Staron, M. Zucker, S. Pardi, S. Maybaum, D. Mancini, Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N. Engl. J. Med. 350, 767\u2013776 (2004)","journal-title":"N. Engl. J. Med."},{"key":"506_CR27","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1056\/NEJMoa053569","volume":"355","author":"RN Nijs De","year":"2006","unstructured":"R.N. De Nijs, J.W. Jacobs, W.F. Lems, R.F. Laan, A. Algra, A.M. Huisman, E. Buskens, C.E. de Laet, A.C. Oostveen, P.P. Geusens, G.A. Bruyn, B.A. Dijkmans, J.W. Bijlsma, Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N. Engl. J. Med. 355, 675\u2013684 (2006)","journal-title":"N. Engl. J. Med."},{"key":"506_CR28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/s10165-008-0055-y","volume":"18","author":"S Takeda","year":"2008","unstructured":"S. Takeda, H. Kaneoka, Saito T Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol. Mod. Rheumatol. 18, 271\u2013276 (2008)","journal-title":"Mod. Rheumatol."},{"key":"506_CR29","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3899\/jrheum.080168","volume":"35","author":"Y Okada","year":"2008","unstructured":"Y. Okada, M. Nawata, S. Nakayamada, K. Saito, Y. Tanaka, Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy. J. Rheumatol. 35, 2249\u20132254 (2008)","journal-title":"J. Rheumatol."},{"key":"506_CR30","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","volume":"42","author":"S Cohen","year":"1999","unstructured":"S. Cohen, R.M. Levy, M. Keller, E. Boling, R.D. Emkey, M. Greenwald, T.M. Zizic, S. Wallach, K.L. Sewell, B.P. Lukert, D.W. Axelrod, A.A. Chines, Risedronate therapy prevents corticosteroid induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 42, 2309\u20132318 (1999)","journal-title":"Arthritis Rheum."},{"key":"506_CR31","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","volume":"15","author":"DM Reid","year":"2000","unstructured":"D.M. Reid, R.A. Hughes, R.F. Laan, N.A. Sacco-Gibson, D.H. Wenderoth, S. Adami, R.A. Eusebio, J.P. Devogelaer, Efficacy and safety of daily risedronate in the treatment of corticosteroid induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J. Bone Miner. Res. 15, 1006\u20131013 (2000)","journal-title":"J. Bone Miner. Res."},{"key":"506_CR32","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","volume":"67","author":"S Wallach","year":"2000","unstructured":"S. Wallach, S. Cohen, D.M. Reid, R.A. Hughes, D.J. Hosking, R.F. Laan, S.M. Doherty, M. Maricic, C. Rosen, J. Brown, I. Barton, A.A. Chines, Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif. Tissue Int. 67, 277\u2013285 (2000)","journal-title":"Calcif. Tissue Int."},{"key":"506_CR33","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00223-001-1060-8","volume":"69","author":"DM Reid","year":"2001","unstructured":"D.M. Reid, S. Adami, J.P. Devogelaer, Chines AA Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif. Tissue Int. 69, 242\u2013247 (2001)","journal-title":"Calcif. Tissue Int."},{"key":"506_CR34","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s002239900334","volume":"61","author":"Y Boutsen","year":"1997","unstructured":"Y. Boutsen, J. Jamart, W. Esselinckx, M. Stoffel, Devogelaer JP Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcif. Tissue Int. 61, 266\u2013271 (1997)","journal-title":"Calcif. Tissue Int."},{"key":"506_CR35","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1359\/jbmr.2001.16.1.104","volume":"16","author":"Y Boutsen","year":"2001","unstructured":"Y. Boutsen, J. Jamart, W. Esselinckx, J.P. Devogelaer, Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3\u00a0months, and calcium alone. J. Bone Miner. Res. 16, 104\u2013112 (2001)","journal-title":"J. Bone Miner. Res."},{"issue":"9671","key":"506_CR36","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","volume":"373","author":"DM Reid","year":"2009","unstructured":"D.M. Reid, J.P. Devogelaer, K. Saag, C. Roux, C.S. Lau, J.Y. Reginster, P. Papanastasiou, A. Ferreira, F. Hartl, T. Fashola, P. Mesenbrink, P.N. Sambrook, Zoledronic acid and risedronate in the prevention andtreatment ofglucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomized controlled trial. Lancet 373(9671), 1253\u20131263 (2009)","journal-title":"Lancet"},{"key":"506_CR37","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.bone.2011.10.024","volume":"50","author":"PN Sambrook","year":"2012","unstructured":"P.N. Sambrook, C. Roux, J.P. Devogelaer, K. Saag, C.S. Lau, J.Y. Reginster, C. Bucci-Rechtweg, G. Su, D.M. Reid, Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. Bone 50, 289\u2013295 (2012)","journal-title":"Bone"},{"key":"506_CR38","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00198-003-1425-0","volume":"14","author":"JD Ringe","year":"2003","unstructured":"J.D. Ringe, A. Dorst, H. Faber, K. Ibach, Sorenson F Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos. Int. 14, 801\u2013807 (2003)","journal-title":"Osteoporos. Int."},{"key":"506_CR39","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3109\/03009742.2012.664647","volume":"41","author":"M Hakala","year":"2012","unstructured":"M. Hakala, H. Kr\u00f6ger, H. Valleala, T. Hienonen-Kempas, M. Lehtonen-Veromaa, J. Heikkinen, T. Tuomiranta, P. Hannonen, L. Paimela, ONCE Trial Group, Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial. Scand. J. Rheumatol. 41, 260\u2013266 (2012)","journal-title":"Scand. J. Rheumatol."},{"key":"506_CR40","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","volume":"357","author":"KG Saag","year":"2007","unstructured":"K.G. Saag, E. Shane, S. Boonen, F. Mar\u00edn, D.W. Donley, K.A. Taylor, G.P. Dalsky, R. Marcus, Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N. Engl. J. Med. 357, 2028\u20132039 (2007)","journal-title":"N. Engl. J. Med."},{"key":"506_CR41","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","volume":"60","author":"KG Saag","year":"2009","unstructured":"K.G. Saag, J.R. Zanchetta, J.P. Devogelaer, R.A. Adler, R. Eastell, K. See, J.H. Krege, K. Krohn, M.R. Warner, Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthr. Rheum. 60, 3346\u20133355 (2009)","journal-title":"Arthr. Rheum."},{"key":"506_CR42","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/acr.20295","volume":"62","author":"JM Grossman","year":"2010","unstructured":"J.M. Grossman, R. Gordon, V.K. Ranganath, C. Deal, L. Caplan, W. Chen, J.R. Curtis, D.E. Furst, M. McMahon, N.M. Patkar, E. Volkmann, K.G. Saag, American College of Rheumatology 2010 recommendations for the prevention and treatment ofglucocorticoid-induced\u00a0osteoporosis. Arthritis Care Res. 62, 1515\u20131526 (2010)","journal-title":"Arthritis Care Res."},{"key":"506_CR43","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1136\/ard.2007.072157","volume":"66","author":"JN Hoes","year":"2007","unstructured":"J.N. Hoes, J.W. Jacobs, M. Boers, D. Boumpas, F. Buttgereit, N. Caeyers, E.H. Choy, M. Cutolo, J.A. Da Silva, G. Esselens, L. Guillevin, I. Hafstrom, J.R. Kirwan, J. Rovensky, A. Russell, K.G. Saag, B. Svensson, R. Westhovens, H. Zeidler, J.W. Bijlsma, EULAR evidence-based recommendations on the management of systemic glucocorticoidtherapy in rheumatic diseases. Ann. Rheum. Dis. 66, 1560\u20131567 (2007)","journal-title":"Ann. Rheum. Dis."},{"key":"506_CR44","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1136\/annrheumdis-2013-203249","volume":"72","author":"N Duru","year":"2013","unstructured":"N. Duru, M.C. van der Goes, J.W. Jacobs, T. Andrews, M. Boers, F. Buttgereit, N. Caeyers, M. Cutolo, S. Halliday, J.A. Da Silva, J.R. Kirwan, D. Ray, J. Rovensky, G. Severijns, R. Westhovens, J.W. Bijlsma, EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann. Rheum. Dis. 72, 1905\u20131913 (2013)","journal-title":"Ann. Rheum. Dis."},{"key":"506_CR45","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s00198-012-1958-1","volume":"23","author":"S Lekamwasam","year":"2012","unstructured":"S. Lekamwasam, J.D. Adachi, D. Agnusdei, J. Bilezikian, S. Boonen, F. Borgstr\u00f6m, C. Cooper, A. Diez Perez, R. Eastell, L.C. Hofbauer, J.A. Kanis, B.L. Langdahl, O. Lesnyak, R. Lorenc, E. McCloskey, O.D. Messina, N. Napoli, B. Obermayer-Pietsch, S.H. Ralston, P.N. Sambrook, S. Silverman, M. Sosa, J. Stepan, G. Suppan, D.A. Wahl, J.E. Compston, I.O.F.-E.C.T.S.G.I.O. Joint, Guidelines Working Group. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos. Int. 23, 2257\u20132276 (2012)","journal-title":"Osteoporos. Int."},{"key":"506_CR46","first-page":"143","volume":"65","author":"M Varenna","year":"2013","unstructured":"M. Varenna, F. Bertoldo, M. Di Monaco, A. Giusti, G. Martini, Rossini M. Safety profile of drugs used in the treatment of osteoporosis: a systematical review of the literature Reumatismo 65, 143\u2013166 (2013)","journal-title":"Safety profile of drugs used in the treatment of osteoporosis: a systematical review of the literature Reumatismo"},{"key":"506_CR47","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jbspin.2012.08.005","volume":"80","author":"E Lespessailes","year":"2013","unstructured":"E. Lespessailes, Bisphosphonates and glucocorticoid-induced osteoporosis: efficacy and tolerability. Joint Bone Spine 80, 258\u2013264 (2013)","journal-title":"Joint Bone Spine"},{"key":"506_CR48","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s00198-006-0073-6","volume":"17","author":"M Rossini","year":"2006","unstructured":"M. Rossini, G. Bianchi, O. Di Munno, S. Giannini, S. Minisola, L. Sinigaglia, S. Adami, Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos. Int. 17, 914\u2013921 (2006)","journal-title":"Osteoporos. Int."},{"key":"506_CR49","first-page":"728","volume":"29","author":"M Rossini","year":"2011","unstructured":"M. Rossini, O. Di Munno, D. Gatti, S. Giannini, S. Minisola, M. Varenna, S. Adami, Optimising bisphosphonate treatment outcomes in postmenopausal osteoporosis: review and Italian experience. Clin. Exp. Rheumatol. 29, 728\u2013735 (2011)","journal-title":"Clin. Exp. Rheumatol."},{"key":"506_CR50","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/BF02556671","volume":"41","author":"S Adami","year":"1987","unstructured":"S. Adami, A.K. Bhalla, R. Dorizzi, F. Montesanti, S. Rosini, G. Salvagno, V. Lo Cascio, The acute-phase response after bisphoshonate administration. Calcif. Tissue Int. 41, 326\u2013333 (1987)","journal-title":"Calcif. Tissue Int."},{"key":"506_CR51","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","volume":"22","author":"S Khosla","year":"2007","unstructured":"S. Khosla, D. Burr, J. Cauley, D.W. Dempster, P.R. Ebeling, D. Felsenberg, R.F. Gagel, V. Gilsanz, T. Guise, S. Koka, L.K. McCauley, J. McGowan, M.D. McKee, S. Mohla, D.G. Pendrys, L.G. Raisz, S.L. Ruggiero, D.M. Shafer, L. Shum, S.L. Silverman, C.H. Van Poznak, N. Watts, S.-B. Woo, E. Shane, Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 22, 1479\u20131491 (2007)","journal-title":"J. Bone Miner. Res."},{"key":"506_CR52","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3899\/jrheum.080759","volume":"36","author":"AA Khan","year":"2009","unstructured":"A.A. Khan, G.K. S\u00e1ndor, E. Dore, A.D. Morrison, M. Alsahli, F. Amin, E. Peters, D.A. Hanley, S.R. Chaudry, B. Lentle, D.W. Dempster, F.H. Glorieux, A.J. Neville, R.M. Talwar, C.M. Clokie, M.A. Mardini, T. Paul, S. Khosla, R.G. Josse, S. Sutherland, D.K. Lam, R.P. Carmichael, N. Blanas, D. Kendler, S. Petak, L.G. Ste-Marie, J. Brown, A.W. Evans, L. Rios, J.E. Compston, Canadian Taskforce on Osteonecrosis of the Jaw. Bisphosphonate associated osteonecrosis of the jaw. J. Rheumatol. 36, 478\u2013490 (2009)","journal-title":"J. Rheumatol."},{"key":"506_CR53","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s00198-012-2239-8","volume":"24","author":"M Mozzati","year":"2013","unstructured":"M. Mozzati, V. Arata, G. Gallesio, Tooth extraction in osteoporotic patients taking oral bisphosphonates. Osteoporos. Int. 24, 1707\u20131712 (2013)","journal-title":"Osteoporos. Int."},{"key":"506_CR54","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bone.2010.05.019","volume":"47","author":"A Giusti","year":"2010","unstructured":"A. Giusti, N.A. Hamdy, S.E. Papapoulos, Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case\/case series studies. Bone 47, 169\u2013180 (2010)","journal-title":"Bone"},{"key":"506_CR55","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jbmr.233","volume":"26","author":"Z Wang","year":"2011","unstructured":"Z. Wang, T. Bhattacharyya, Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007. J. Bone Miner. Res. 26, 553\u2013560 (2011)","journal-title":"J. Bone Miner. Res."},{"key":"506_CR56","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s00198-007-0349-5","volume":"18","author":"O Strom","year":"2007","unstructured":"O. Strom, F. Borgstrom, S.S. Sen, S. Boonen, P. Haentjens, O. Johnell, J.A. Kanis, Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries\u2014an economic evaluation based on the fracture intervention trial-. Osteoporos. Int. 18, 1047\u20131061 (2007)","journal-title":"Osteoporos. Int."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-014-0506-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-014-0506-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-014-0506-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T14:37:53Z","timestamp":1566311873000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-014-0506-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,4]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["506"],"URL":"https:\/\/doi.org\/10.1007\/s12020-014-0506-5","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,4]]}}}